Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (102)	9/18/2003 5:31:19 PM
From: SemiBull	Read Replies (1) \| Respond to of 671

Comprehensive interference RNAi-sensitive Drosophila cells provide insights into lamella formation and motor protein specificity \| By David Secko biomedcentral.com

To: tuck who wrote (102)	9/20/2003 9:34:12 AM
From: nigel bates	Respond to of 671

Drug Discovery & Development Very interesting article. Clearly it's a little too early to get wildly excited about therapeutic use - Usman expects his company to file an IND with an RNAi-based drug by early 2005 - and that's from a company with experience of producing RNA for in vivo delivery... and it may well not work first time out...and the number of addressable disease targets seems limited. Compared with (say) fully human mABs, which ostensibly present fewer development problems, and looking at how long it's taken companies like ABGX and MEDX to start realising their potential, I suspect it will make sense to sit on the sidelines for some time yet. OTOH, LEXG must hate this stuff.